MET and neoplasm: In CRC in particular, overexpression of C-MET is associated with advanced tumor stages, appears to stimulate VEGF-A (vascular endothelial growth fator-A) production and thus angiogenesis in tumor cells, and promotes therapy resistance in patients treated with anti-EGFR monoclonal antibodies3.